HOME > News > Press Releases > 2023.11.24 Glac Biotech’s Totipro® PE0401 Wins Global Recognition at the NutraIngredients Awards

News

2023.11.24 Glac Biotech’s Totipro® PE0401 Wins Global Recognition at the NutraIngredients Awards

Share to
The stage was global, the competition fierce — and Glac Biotech’s Totipro® PE0401 emerged victorious. At the 2023 NutraIngredients Awards, often called the “Oscars” of the nutrition industry, PE0401 was honored for its outstanding contribution to microbiome modulation, confirming its status as a world-class innovation in postbiotics.

Raising the Bar in Postbiotics
The NutraIngredients Awards are among the most prestigious recognitions in functional food and supplement ingredients. To stand out requires not only innovation, but also robust science and proven results. Glac Biotech’s achievement demonstrates that PE0401 isn’t just another raw material — it’s a benchmark in safety, functionality, and efficacy.
This accolade has turned the spotlight on Glac’s postbiotic expertise, drawing even greater attention from international ingredient suppliers and brand owners eager to incorporate PE0401 into their products.

Why Postbiotics? Stability Meets Science
Probiotics are widely known for supporting gut health, but as living organisms, they come with limitations — requiring careful storage and handling. Postbiotics, on the other hand, are the beneficial compounds created during fermentation. Heat-stable, acid-resistant, and versatile, they open up entirely new applications.
Glac Biotech pushed the field further by developing a multi-strain postbiotic rather than relying on single strains. This innovation gives PE0401 a unique edge, enabling it to deliver superior benefits proven in human trials.

The Science Behind Totipro® PE0401
PE0401 is produced through 48 hours of precision fermentation using a blend of four probiotic strains:
  • Lactobacillus salivarius AP-32
  • Lactobacillus acidophilus TYCA06
  • Lactobacillus plantarum LPL28
  • Bifidobacterium infantis BLI-02
Backed by studies ranging from in vitro to animal and human clinical trials, PE0401 has been shown to:
  • Strengthen intestinal mucosal integrity
  • Regulate gut inflammation
  • Support systemic immune balance
  • Promote healthier gut flora through synergy with live probiotics
With patents spanning the U.S., China, EU, Thailand, and Taiwan, and recognition in SCI-indexed journals, PE0401 is no longer just an ingredient — it’s a global leader.

Building a Family of Postbiotic Solutions
While PE0401 shines in lower digestive health, Glac has also expanded its Totipro® line to include PE0301, targeting oral and upper digestive wellness. Together, they represent a comprehensive postbiotic solution designed to care for the body from mouth to gut.

A Commitment to Global Health
Glac Biotech’s victory at the NutraIngredients Awards is more than a trophy — it’s a promise. With every innovation, the company is delivering safe, effective, and scientifically proven health solutions for businesses and consumers alike.
Totipro® PE0401 has proven that postbiotics can redefine the future of gut health. And with Glac Biotech’s relentless pursuit of science, the best is still to come.
 

Media Coverage (Extended Reading)

Previous Back to list Next
Back
TOP